Meeting
2015 Genitourinary Cancers Symposium
Characterization of abiraterone responses in African American castrate resistant prostate cancer.
Authors
Michael Stolten
Tulane University School of Medicine, New Orleans, LA
Michael Stolten , Elisa M. Ledet , Allison H. Feibus , Brian E. Lewis , Jonathan L. Silberstein , Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 203)
DOI
10.1200/jco.2015.33.7_suppl.203
Abstract #
203
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers.
First Author: Robert Stevenson
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival in Black and non-Black patients with metastatic prostate cancer.
First Author: Nina Cheranda